Stock SORRENTO THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Sorrento Therapeutics Inc Other OTC

Equities

US83587F1030

Biotechnology & Medical Research

End-of-day quote Other OTC
Other stock markets
- USD - Intraday chart for Sorrento Therapeutics Inc
Mar. 15 Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs MT
Mar. 12 News Highlights : Top Company News of the Day - Tuesday at 5 AM ET DJ

Business Summary

Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.

Sales per Business

USD in Million2021Weight2022Weight Delta
Scilex
60.5 %
29 54.0 % 38 60.5 % +33.24%
Sorrento Therapeutics
39.5 %
24 46.0 % 25 39.5 % +1.84%

Sales per region

USD in Million2021Weight2022Weight Delta
United States
100.0 %
53 100.0 % 63 100.0 % +18.78%

Managers

Managers TitleAgeSince
Henry Ji CEO
 Chief Executive Officer 59 88-12-31
Shawn Sahebi COO
 Chief Operating Officer - -
Mike A. Royal CTO
 Chief Tech/Sci/R&D Officer 70 14-03-02
Dorman Followwill BRD
 Director/Board Member 60 17-09-30
Jaisim Shah BRD
 Director/Board Member 63 13-09-10
Brian Cooley IRC
 Investor Relations Contact - -
William Farley SAM
 Sales & Marketing 68 -
Alexis Nahama PRN
 Corporate Officer/Principal - 17-01-31
Mark R. Brunswick LAW
 General Counsel - 16-12-31
Mohsin Meghji PRN
 Corporate Officer/Principal 60 -

Members of the board

Members of the board TitleAgeSince
Kim D. Janda BRD
 Director/Board Member 67 12-03-31
David Lemus BRD
 Director/Board Member 61 17-09-30
Jaisim Shah BRD
 Director/Board Member 63 13-09-10
Yue Wu BRD
 Director/Board Member 60 16-07-31
Henry Ji CEO
 Chief Executive Officer 59 88-12-31
Dorman Followwill BRD
 Director/Board Member 60 17-09-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 558,849,336 546,375,093 ( 97.77 %) 7,568,182 ( 1.354 %) 97.77 %

Shareholders

NameEquities%Valuation
The Vanguard Group, Inc.
5.358 %
29,535,954 5.358 % 236 288 $
Henry Ji
1.560 %
8,597,498 1.560 % 68 780 $
ETF Managers Group LLC
0.0213 %
117,646 0.0213 % 941 $
Jaisim Shah
0.0204 %
112,633 0.0204 % 901 $
swisspartners Marcuard Heritage AG
0.0200 %
110,000 0.0200 % 880 $
Lattice Capital Management LLC
0.009396 %
51,800 0.009396 % 414 $
Arabesque Asset Management Ltd.
0.006031 %
33,250 0.006031 % 266 $
KLCM Advisors, Inc.
0.005442 %
30,000 0.005442 % 240 $
HighPoint Advisor Group LLC
0.004036 %
22,250 0.004036 % 178 $
Slatestone Wealth LLC
0.003888 %
21,433 0.003888 % 171 $

Holdings

NameEquities%Valuation
SCILEX HOLDING COMPANY
1.15%
 1,917,210 1.15% 3,048,364 $
CELULARITY INC.
2.32%
 505,043 2.32% 2,641,375 $

Company contact information

Sorrento Therapeutics, Inc.

4955 Directors Place

92121, San Diego

+858 203 4100

http://sorrentotherapeutics.com
address Sorrento Therapeutics Inc

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per Business

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.65% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.28% 96.84B
ARGENX SE Stock argenx SE
-0.44% 21.48B
BIONTECH SE Stock BioNTech SE
-18.47% 20.82B
GENMAB A/S Stock Genmab A/S
-7.45% 18.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.70% 16.81B
BEIGENE, LTD. Stock BeiGene, Ltd.
-25.00% 13.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.58% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+22.57% 11.06B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SRNE Stock
  4. Stock
  5. Company Sorrento Therapeutics Inc